Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker Corporation (NASDAQ: BRKR) has announced a quarterly cash dividend payment approved by its Board of Directors. The company will distribute $0.05 per share to stockholders. The dividend will be paid on June 27, 2025, to shareholders of record as of June 16, 2025.
Bruker Corporation (BRKR) has announced a global settlement with 10x Genomics to resolve their ongoing patent disputes. The settlement includes global patent cross-license agreements between both companies and will result in the dismissal of all pending lawsuits and administrative proceedings in multiple countries, including the United States, Germany, and before the European Unified Patent Court.
According to Mark R. Munch, Ph.D., President of the Bruker Nano Group, this resolution ensures that the scientific community can continue their research using Bruker's CosMx® and GeoMx® spatial biology platforms without concerns about litigation interference, particularly in fields such as oncology and neurobiology.
Bruker Corporation (BRKR) reported Q1 2025 financial results with revenues of $801.4 million, showing an 11.0% year-over-year increase. The company's Bruker Scientific Instruments (BSI) segment demonstrated strong performance with 5.1% organic revenue growth, while Q1 2025 GAAP diluted EPS was $0.11 and non-GAAP diluted EPS was $0.47, down 11.3% year-over-year.
Due to academic market and tariff challenges, Bruker has revised its FY 2025 guidance, now expecting revenues between $3.48 to $3.55 billion (3.5% to 5.5% growth) and non-GAAP EPS of $2.40 to $2.48 (0% to 3% growth). The company plans to implement cost and pricing initiatives, along with supply network re-engineering, to mitigate more than half of the new headwinds in 2025.
Bruker (BRKR) announced major advancements in spatial biology and multiomics research at AACR 2025. Key developments include:
- CosMx 2.0 upgrade offering 2X increase in RNA detection efficiency
- New same-slide multiomics feature analyzing whole transcriptome (~19,000 targets) and immuno-oncology proteins (up to 76 proteins)
- Introduction of nCounter Platform with multiomic capabilities for simultaneous RNA and protein analysis
The company will begin taking advance orders for CosMx Whole Transcriptome (WTX) assay in May, with commercial shipments in summer. The nCounter Multiomics with Immune Pathways Protein panel and Tumor Signaling Protein panel will be commercially available in second half of 2025.
Bruker (Nasdaq: BRKR) announced the launch of Beacon Discovery™ Optofluidic System, a new benchtop system for live single-cell functional analysis, at the AACR Annual Meeting 2025. The system features Bruker's proprietary Opto-Electrical Positioning technology and OptoSelect™ microfluidic chips.
The compact Beacon Discovery complements existing premium Beacon® platforms with a lower cost of ownership and reduced running costs. It offers precise single-cell isolation, control, and analysis capabilities using machine learning automation. The system enables multi-parameter temporal analysis over extended periods, combining live-cell imaging with sequential assays.
Targeting academic and biotech laboratories, Beacon Discovery focuses on applications in immuno-oncology, infectious diseases, autoimmune disorders, and immune profiling. Commercial shipments are expected later in 2025, with pre-orders now available.